Boston, MA 03\/21\/2014 (wallstreetpr) – Shares of the medtech company IsoRay, Inc. (NYSEMKT:ISR)<\/b> swung into massive gains once more for the second day Thursday. The shares closed at $3.30, up 29.41 percent, and having surged to new one-year high earlier in the session. That was a positive tracking of the Wednesday big gain where the shares went up as much as 80 percent on solid volume of shares changing hands.<\/p>\n
The noted gain in the shares have nothing in itself, only that it is the outward manifestation of the growing optimism in the stock. We take a closer look at IsoRay, Inc. (NYSEMKT:ISR) on the basis of the positive news that helped propel the stock and how much gas, if any, the stock has to continue rising.<\/p>\n
Promising cancer treatment technology<\/b><\/p>\n
News emerged after markets opened Wednesday that IsoRay\u2019s brachytheraopy Cesium-131 was successfully used to treat an aggressive type of cancer in a junior patient. The news implied that the treatment technique held promise to treating of aggressive forms of cancer. The doctor who was involved in the treatment reinforced the positive sentiment about IsoRay\u2019s technology and said the 12-year child who had been tried on other treatments before with the cancer returning had his case solved completely and discharged when Cesium-131 was used.<\/p>\n
With this compelling success already noted on Cesium-131, broad adoption of the treatment could resulting in attractive revenue for the company given that at the moment it bears the monopoly to the technology. At present IsoRay, Inc. (NYSEMKT:ISR) remains in loss position, although its losses have been consistently low of late.<\/p>\n
What if?<\/b><\/p>\n
While the technology is promising and has the potential of propelling IsoRay, Inc. (NYSEMKT:ISR) up in both earnings and stock price, it might to catastrophic for the company and its shareholders if the cancer treatment technique fails to pan out. Thus, investors should avoid hurried decisions in this stock and instead keep a closer eye on the developments around Cesium-131. Also, it is important to note that stocks which leap upwards so quickly typically have the tendency of suffering equally quick negative swings, especially in small cap and tiny float companies like IsoRay, Inc. (NYSEMKT:ISR).<\/p>\n","protected":false},"excerpt":{"rendered":"
Boston, MA 03\/21\/2014 (wallstreetpr) – Shares of the medtech company IsoRay, Inc. (NYSEMKT:ISR) swung into massive gains once more for the second day Thursday. The […]<\/p>\n","protected":false},"author":32,"featured_media":17720,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[5326,5327],"stock_ticker":[],"class_list":["post-17713","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-isoray-inc-nysemktisr","tag-nysemktisr","entry"],"acf":[],"yoast_head":"\n